「ldl」の共起表現一覧(1語右で並び替え)
該当件数 : 56件
| nation with niacin to reduce blood cholesterol ( | LDL and VLDL). |
| f combined hyperlipidemia, effectively reducing | LDL and triglycerides and improving HDL levels. |
| nd treatment guidelines for apoB in addition to | LDL and non-HDL in high-risk patients. |
| tural hypotension.Alpha-1 blockers may decrease | LDL and triglycerides and increase HDL. |
| which leads indirectly to a modest reduction in | LDL and increase in HDL. |
| reased blood cholesterol levels (12 to 25 mg/dl | LDL and 8 to 10 mg/dl HDL at medium dosage levels) |
| cholesterol levels) characterised by increased | LDL and triglyceride concentrations, often accompan |
| nimal from harmful forms of cholesterol such as | LDL and VLDL. |
| ipoproteins (IDL) and low density lipoproteins ( | LDL), and can assemble VLDL particles in the liver. |
| rates, it reduces both low-density lipoprotein ( | LDL) and very low density lipoprotein (VLDL) levels |
| not successful at reducing cholesterol levels, | LDL apheresis may be used; this filters LDL from th |
| Low density lipoproteins ( | LDL) carry cholesterol from the liver to cells of t |
| It helps to lower | LDL cholesterol and triglyceride in the blood, and |
| to reduce the level of low-density lipoprotein ( | LDL) cholesterol in blood when ingested. |
| It was shown that the levels of the | LDL cholesterol decreased, while that of HDL choles |
| Later projects include investigation of | LDL cholesterol receptor internalization, cellular |
| s reduce high cholesterol by reducing the "bad" | LDL cholesterol levels. |
| The test subjects saw a 7-percent decrease in | LDL cholesterol with no change in total cholesterol |
| f about 2 grams per day provides a reduction in | LDL cholesterol of about 10 percent. |
| bute to the hunger cycle, they do contribute to | LDL cholesterol and heart disease. |
| hat myricetin in high concentrations can modify | LDL cholesterol such that uptake by white blood cel |
| uts such as almonds and walnuts can lower serum | LDL cholesterol concentrations. |
| oxygen species, which is linked to oxidation of | LDL cholesterol and resultant cardiovascular effect |
| d as a nutritional supplement intended to lower | LDL cholesterol ("bad" cholesterol) and increase HD |
| ere undertaken, in which dramatic reductions in | LDL cholesterol were observed, with very few advers |
| evels of both total cholesterol (145 mg/dl) and | LDL cholesterol (82 mg/dl). |
| erol, a modest increase in palmitic acid raises | LDL cholesterol relative to oleic acid, even when d |
| r than 40 mg/dl, in addition to strong reducing | LDL cholesterol (-40%). |
| nt-food diet is associated with favorable serum | LDL cholesterol and triglycerides but also with ele |
| decrease of | LDL cholesterol), and affects the quality of life w |
| 62-percent drop in low-density lipoproteins, or | LDL cholesterol, when researchers supplemented test |
| sting tachycardia, hypertension, high total and | LDL cholesterol, and low HDL cholesterol, and elect |
| re substantially elevated by native or oxidized | LDL cholesterol. |
| t a monounsaturated fatty acid in its effect on | LDL cholesterol. |
| At 100 mg dosage, | LDL decreased by 36% while HDL increased by 138%. |
| Lipoproteins (chylomicrons, VLDL, | LDL, HDL) |
| nents that make up total cholesterol reading -- | LDL, HDL, and VLDL -- are also important in measuri |
| Phase III trial to assess the drug's effects on | LDL, HDL, clinically measurable cardiovascular even |
| spiralling effect occurs with high endothelial | LDL levels causing greater ADMA values, which in tu |
| for patients with metabolic syndrome with high | LDL, low HDL and diabetes mellitus. |
| l Education Program ATP III recommendations for | LDL measurement and the only commercially available |
| 2000 they used Bristol Lodekkas, this time the | LDL model (a longer version of the LD) with a Gardi |
| mation of atherogenic oxidised-LDL, the form of | LDL present in foam cells of an atheromatous plaque |
| receptor 1) also known as lectin-type oxidized | LDL receptor 1 (LOX-1) is a protein that in humans |
| via interaction between apolipoproteinE and the | LDL receptor or Lipoprotein receptor-related protei |
| rotein E Receptor 2; ApoER2) is a member of the | LDL receptor family that plays a role in endocytosi |
| LDL receptor type A (LA) repeats of 40 residues eac | |
| sity-lipoprotein-L-serine O-phosphotransferase, | LDL receptor kinase, [low-density-lipoprotein] kina |
| n be found in all receptors of the gene family, | LDL receptor and certain isoforms of ApoER2 and VLD |
| The | LDL receptors are minimally functional, if at all. |
| The lack of sufficient | LDL receptors is implicated in familial hypercholes |
| that human cells have low-density lipoprotein ( | LDL) receptors that extract cholesterol from the bl |
| this provides a liver with normally functional | LDL receptors, and leads to rapid improvement of th |
| identified a modified low-density lipoprotein ( | LDL) that contributes to atherosclerosis in humans. |
| cluding the number of Low Density Lipoproteins ( | LDL), the most atherogenic of the lipoproteins. |
| Initially, most VLDL is converted into | LDL until this mechanism is saturated, after which |
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると
|
検索履歴を保存できる！
こんにちは ゲスト さん
|
ログイン |
Weblio会員(無料)になると
|
